In context
CagriSema refers to coadministration of cagrilintide and semaglutide. Phase 3 trials examined weight outcomes in adults with overweight or obesity, in populations with and without type 2 diabetes. [1–2]
At a glance
- Type
- Combination programme
- Regulatory context
- The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.
- Evidence
- A combination programme is not a new single peptide. Its findings cannot be transferred automatically to untested mixtures or formulations.
How to interpret this evidence
A combination programme is not a new single peptide. Its findings cannot be transferred automatically to untested mixtures or formulations. [1] [2]
Safety and clinical context
The evidence described here does not establish safety for unsupervised use. Product identity, route, formulation, interactions and long-term effects cannot be inferred from a study category.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. pubmed.ncbi.nlm.nih.gov
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. pubmed.ncbi.nlm.nih.gov